Fondaparinux in Patients with Impaired Renal Function: The Right Choice?

  1. Giuseppe Famularo, MD, PhD; and
  2. Giovanni Minisola, MD
  1. From San Camillo Hospital, Rome 00152, Italy.

    TO THE EDITOR:

    Investigators from OASIS-5 (Fifth Organization to Assess Strategies in Acute Ischemic Syndromes) (1) report more bleeding events with enoxaparin than with fondaparinux among patients with non–ST-segment elevation myocardial infarction. However, because fondaparinux has a longer half-life than enoxaparin (17 hours vs. <10 hours) (2, 3), we are concerned that the trial failed to demonstrate that enoxaparin is safer than fondaparinux in patients with impaired renal function, which …

    [Full Text of this Article]
    « Previous | Next Article »Table of Contents

    This Article

    1. Ann Intern Med April 1, 2008 vol. 148 no. 7 561
    1. » Excerpt
    2. Full Text
    3. Full Text (PDF)

    Rapid Responses

    1. Submit a response
    2. No responses published

    Current Issue

    1. November 17, 2009, 151 (10)
    1. Alert me to current issues